Whole organism based techniques and approaches in early stage oncology drug discovery-patents and trends

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 5, Issue 3, 2011, Pages 183-191

  Hampson, Richard J ^a   Wyatt, Michael D ^b  

^a Thelial Technologies SA   (Portugal)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Caenorhabditis elegans; Cancer; Danio rerio; Dictyostelium discoideum; Drosophila melanogaster; Early stage drug discovery; Hit; Lead; Whole organism

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; GOSSYPOL; LONAFARNIB; PROTEIN BCL 2; PROTEIN MYB; RETINOBLASTOMA PROTEIN; TIPIFARNIB; VISMODEGIB;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CAENORHABDITIS ELEGANS; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COLON CANCER; DICTYOSTELIUM; DICTYOSTELIUM DISCOIDEUM; DNA DAMAGE; DNA REPAIR; DROSOPHILA; DROSOPHILA MELANOGASTER; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; GENETIC ASSOCIATION; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; NONHUMAN; ONCOGENE; PATENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; ZEBRA FISH;

ANIMALS; ANTINEOPLASTIC AGENTS; CAENORHABDITIS ELEGANS; DICTYOSTELIUM; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; PATENTS AS TOPIC; ZEBRAFISH;

EID: 80052854155     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221411797265944     Document Type: Article

References (71)

1. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, et al. Global Cancer Facts & Figures 2007. American Cancer Society: Atlanta 2007.
2. World Health Organisation. Fact sheet 297. Avaliable at: http://www.who.int/mediacentre/factsheets/fs297/en/index.html [Accessed on: February 10, 2011].
3. Meropol NJ, Schulman KA. Cost of cancer care: Issues and implications. J Clin Oncol 2007; 25: 180-6.
4. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat Rev Drug Dis 2010; 9: 203-14.
5. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003; 22: 151-85.
6. Austin DH. Research and development in the pharmaceutical industry, Congressional Budget Office Report, October 2006, http://www.cbo.gov/ftpdocs/76xx/doc7615/10-02-DrugR-D.pdf. [Accessed on:September 16, 2010].
7. Kola I. The state of innovation and drug development. Clin Pharmacol Ther 2008; 4: 78-84.
8. Zaenker KS, Entschladen F. Paving roads for new drugs in oncology. Recent Pat Anticancer Drug Discov 2009; 4: 137-45.
9. Shoemaker RH. The NCI human tumour cell line anticancer drug screen. Nat Rev Cancer 2006; 6: 813-23.
10. Liu H, D'Andrade P, Fulmer-Smentek S, Philip Lorenzi P, Kohn KW, Weinstein JM, et al. mRNA and microRNA Expression Profiles of the NCI-60 Integrated with Drug Activities. Mol Cancer Ther 2010; 9: 1080-91.
11. Fogarty, P. In vivo high throughput toxicology screening method. US6365129 (2002) & US6845504 (2005).
12. McElvany KD. FDA investigational new drug requirements. Front Neurol Neurosci 2009; 25: 46-9.
13. Williams JG. Dictyostelium finds new roles to model. Genetics 2009; 185 (3): 717-26.
14. Lieschke GJ, Currie PD. Animal models of human disease: Zebrafish swim into view. Nat Rev Genet 2007 8 (5): 353-367.
15. Kirienko NV, Mani K, Fay DS. Cancer models in Caenorhabditis elegans. Dev Dyn 2010; 239: 1413-48.
16. Pfleger CM, Reiter LT. Recent efforts to model human diseases in vivo in Drosophila. Fly 2008; 2: 129-32.
17. Bohrer RA. Reach-through claims for drug target patents: Rx for pharmaceutical policy. Nat Biotech 2008; 23: 55-6.
18. Fogarty, P. Non-mammalian transgenic animal model for cellular proliferative diseases. US6316690 (2001).
19. Duyk, G., Karim, F.D. Methods for identifying anti-cancer drug targets. US6489127 (2002).
20. Hafen, E. Function-based small molecular weight compound screening system in Drosophila melanogaster. US6548733 (2003).
21. Dean, M.C., Hahn, H.E., Wicking. C., Christiansen, J., Zaphiropoulos, P.G., Gailani, M.R., Shanley, S.M., Chidambaram, A., Vorechovsky, I., Holmberg-Lindstrom, E., Unden, A.B., Gillies, S.A., Negus, K., McLeod Smyth, I., Pressman, C.L., Leffell, D.J., Gerrard, B., Goldstein, A.M., Wainwright, B., Toftgard, R.C.M., Chenevix-Trench, G., Bale, A.E. Basal cell carcinoma tumor suppressor gene. US6552181 (2003).
22. Dean, M.C., Hahn, H.E., Wicking. C., Christiansen, J., Zaphiropoulos, P.G., Gailani, M.R., Shanley, S.M., Chidambaram, A., Vorechovsky, I., Holmberg-Lindstrom, E., Unden, A.B., Gillies, S.A., Negus, K., McLeod Smyth, I., Pressman, C.L., Leffell, D.J., Gerrard, B., Goldstein, A.M., Wainwright, B., Toftgard, R.C.M., Chenevix-Trench, G., Bale, A.E. Basal cell carcinoma tumor suppressor protein. US7317086 (2008).
23. Keegan, K.P., Stout, T.J. Drosophila homologues of genes and proteins implicated in cancer and methods of use. US6579701 (2003).
24. Su, T.T., Jaklevic, B.R. Methods of identifying and using chemotherapeutic agents. US7695899 (2010).
25. Serbedzija, G.N., Semino, C.E., McGrath, P. Methods for introducing heterologous cells into fish. US6761876 (2004).
26. Serbedzija, G.N., Semino, C.E., Frost, D. Methods of screening agents for activity using teleosts. US6299858 (2001), US7041276 (2006), US7435870 (2008) & US7687682 (2010).
27. Serbedzija, G.N., Seng, W.L., McGrath, P. Methods of screening agents for activity using teleosts. US6656449 (2003).
28. McGrath, P., Parng, C., Serbedzija, G.N. Methods of screening agents for activity using teleosts. US7767880 (2010).
29. Farber, S., Pack, M., Halpern, M. High throughput genetic screening of lipid and cholesterol processing using fluorescent compounds. US7488467 (2009).
30. Mumm, J.S., Schroeter, E.H. Targeted and regional cellular ablation in zebrafish. US7514595 (2009).
31. Hannah, A., Alexander, S. Methods of screening novel agents for use in cancer therapy and prevention. US6867034 (2005).
32. Greenwald, I., Hubbard, E.J. Sel-10 and uses thereof. US6087153 (2000).
33. Verwaert, P., Feichtinger, R., Behgym, M., Bogaert, T. Compound assay. US6664441 (2003).
34. Verwaert, P., Plateeu, C., Cuvillier, G., Bogaert, T. Compound screening method. US6787125 (2004).
35. Horvitz, H.R., Hengartner, M. Identification and characterization of a gene which protects cells from programmed cell death and uses there for. US6902732 (2005).
36. Horvitz, H.R., Conradt, B. EGL-1, a new protein required for programmed cell death in C. elegans that interacts with the BCL-2- like protein CED-9. US6596495 (2003).
37. Horvitz, H.R., Yuan, J., Shaham, S. Cloning sequencing and characterization of two cell death genes and uses there for. US7138510 (2006).
38. Rothman, J.H., Derry, W.B. Methods for identifying novel therapeutics and diagnostics in the p53 pathway. US7196242 (2007).
39. Grandien, K., Rothbladt, J., Concari, P., Quelo, I., Klebl, B. C. elegans p21-activated kinase (PAK) gene and associated loss-of- function phenotypes that facilitate screening for small molecule modulators of PAK activity in the nematode, Caenorhabditis elegans. US7319024 (2008).
40. Horvitz, H.R., Davison, E.M., Lu, X. Tumour suppressor pathway in C. elegans. US7670778 (2010).
41. St. Johnston D. The art and design of genetic screens: Drosophila melanogaster. Nat Rev Genet 2002; 3: 176-88.
42. Stenman G, Anderson MK, Andrén Y. New tricks from an old oncogene: Gene fusion and copy number alterations of MYB in human cancer. Cell Cycle 2010; 9: 2986-95.
43. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
44. Lohmann D. Retinoblastoma. Adv Exp Med Biol 2010; 685: 220-7.
45. van der Heuvel S, Dyson NJ. Conserved functions of the pRB and E2F families. Nat Rev Mol Cel Biol 2008; 9: 713-24.
46. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
47. Blum R, Kloog Y. Tailoring Ras-pathway inhibitor combinations for cancer therapy. Drug Res Updates 2005; 8: 369-80.
48. High A, Zedan W. Basal Cell Nervus Syndrome. Curr Opin Oncol 2005; 17: 160-6.
49. Iwasaki J, Srivastava D, Moy RL, Lin HJ. The molecular genetics underlying basal cell carcinoma. J Am Acad Dermatol 2010; doi:10.1016/j.jaad.2010.06.054.
50. Lorusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor GDC-0449 in patients with refractory, locally-advanced or metastatic solid tumors. Clin Cancer Res 2011;17(8):2502-11.
51. Pérez-Tomás R, Montaner B, Llagostera E, Soto-Cerrato V. The prodigiosins, proapoptotic drugs with anticancer properties. Biochem Pharmacol 2003; 66: 1447-52.
52. Conradt B. Genetic control of programmed cell death during animal development. Ann Rev Genet 2009; 43: 493-523.
53. Bischoff P, Altmeyer A, Dumont F. Radiosensitising agents for the radiotherapy of cancer: Novel molecularly targeted approaches. Expert Opin Ther Pat 2009; 19: 643-62.
54. th Ed., Univ. of Oregon Press, Eugene, 2007.
55. Zon L, Peterson RT. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 2005; 4: 35-44.
56. Doyon Y, McCammon JM, Miller JC, Faraji F, Ngo C, Katibah GE, et al. Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol 2008; 26: 702-8.
57. Meng X, Noyes MB, Zhu LJ, Lawson ND, Wolfe SA. Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases. Nat Biotechnol 2008; 26: 695-701.
58. Nasevicius A, Ekker SC. Effective targeted gene 'knockdown' in zebrafish. Nat Genet 2000; 26: 129-30.
59. Bill BR, Petzold AM, Clark KJ, Schimmenti LA, Ekker SC. A primer for morpholino use in zebrafish. Zebrafish 2009; 6: 69-77.
60. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protocols 2007; 2: 247-50.
61. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
62. Schäfer M, Werner S. Cancer as an overhealing wound: An old hypothesis revisited. Nat Rev Mol Cell Biol 2008; 9: 628-38.
63. de la Chapelle A, Peltomäki P. Genetics of hereditary colon cancer. Ann Rev Genet 1995; 29: 329-48.
64. th ed. Lippincott, Williams & Wilkins 2006.
65. Jäger S, Schwartz HT, Horvitz HR, Conradt B. The Caenorhabditis elegans F-box protein SEL-10 promotes female development and may target FEM-1 and FEM-3 for degradation by the proteasome. Proc Natl Acad Sci 2004; 101: 12549-54.
66. Cecconi F. Apaf1 and the apoptotic machinery. Cell Death Diff 1999; 6: 1087-98.
67. Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned TM, et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007; 110: 2057-66.
68. Lian J, Wu X, He F, Karnak D, Tang W, Meng T, et al. A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death Diff 2010; doi:10.1038/cdd.2010.74.
69. Malkin D, Strong LC, Li FP, Nelson CE, Kim DH, Kassel J, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-8.
70. Lim YP, Lim YP, Lim TT, Chan YL, Yeo BH, Vojtesek B, et al The p53 knowledgebase: An integrated information resource for p53 research. Oncogene 2007; 26: 1517-21.
71. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: Drugging the p53 pathway. Nat Rev Cancer 2009; 9: 862-73.